Tempus AI and Whitehawk Therapeutics Partner to Advance Biomarker-Focused Oncology Research

Tempus AI has announced a multi-year collaboration with Whitehawk Therapeutics to utilize its real-world dataset in advancing biomarker-focused oncology research. The partnership highlights Tempus AI's expanding influence in clinical data, AI, and drug development, further integrating its de-identified multimodal database into next-generation oncology pipelines. This collaboration may shape the company's investment outlook and future growth prospects, but it is unlikely to meaningfully change the most important short-term catalysts, such as volume growth in oncology testing and new pharma data deals.